Acumen Pharmaceuticals, Inc. (ABOS) Stock

Acumen Pharmaceuticals, Inc. (ABOS) is a Healthcare stock trading at $3.16 (as of 2026-08-21), with a market capitalization of $228.24M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer’s disease. Its work centers on ACU193, a humanized monoclonal antibody intended to target soluble amyloid-beta oligomers and currently in Phase I clinical development.

Understand Acumen Pharmaceuticals, Inc.: how it makes money

Acumen Pharmaceuticals develops a targeted immunotherapy drug candidate, ACU193, for Alzheimer’s disease, and it does not have meaningful product revenue reported in the latest quarter.

As a clinical-stage biopharmaceutical company with no meaningful product revenue shown for the latest period, its profit model is structurally driven by whether ACU193 can advance through clinical development, which depends on trial enrollment, active study sites, and patient screening outcomes.

Business quality (Weak): The business is tightly focused on advancing ACU193 through early clinical stages, and investors need to track execution in enrollment and screening, because there is no product revenue base yet to cushion operating losses.

Bull case

  • Trial execution indicators are in motion for the company’s lead program, with 542 individuals enrolled in Altitude-AD early Alzheimer’s disease: Higher and sustained enrollment can support the ability to run the program through its planned study phases.
  • The company reports a sizable operating footprint for Altitude-AD, with 50 active study sites: A broad set of active sites can improve recruitment flexibility and reduce bottlenecks.

Bear case

  • The company is still in clinical-stage development, with ACU193 described as Phase I clinical-stage and the company emphasizing trial advancement rather than commercial products: Clinical outcomes and regulatory progress are uncertain, and there is no product revenue base shown to offset that risk.
  • Screening and patient selection matter, and reported amyloid PET positivity rates vary by screening approach (40% and 81%): Variability in screening results can affect how quickly eligible patients can be identified and enrolled.
Valuation — source: SEC EDGAR (first-party)
Price$3.16
Market Cap$228.24M
Price / Book3.99
Price / Sales44.44
FCF Yield-40.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$7.45M
Net Margin-1629.3%
Revenue Growth (YoY)-44.9%
EPS Growth (YoY)-33.8%
FCF Growth (YoY)-43.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-4.84 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($49.54M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODaniel J. O'Connell
Employees61
CountryUS
IPO Date2022-03-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Alector, Inc. (ALEC)
  • Precision BioSciences, Inc. (DTIL)
  • Coherus Oncology, Inc. (CHRS)
  • Protara Therapeutics, Inc. (TARA)
  • Voyager Therapeutics, Inc. (VYGR)
  • Protalix BioTherapeutics, Inc. (PLX)
  • Armata Pharmaceuticals, Inc. (ARMP)
  • Caribou Biosciences, Inc. (CRBU)
ABOS earnings history · ABOS institutional & insider holders · ABOS KPIs & operating metrics · ABOS financials · ABOS investor presentations & press releases · ABOS SEC filings · ABOS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.